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www.rbmonl ine .comEDITORIALEmbryonic DNA sampling without biopsy: the
beginnings of non-invasive PGD?The clinical usefulness of preimplantation genetic diagnosis
(PGD) and screening (PGS) may be imperative, but it is not
without its shortcomings. A number of arguments, some
reasoned and others not, have been put forth against these
technologies. To avoid transmission of genetic disease, pa-
tients and their doctors who may consider assisted repro-
duction, often choose post-conception testing with the
option of termination of an affected pregnancy rather than
commit to PGD. Moreover, while PGS may offer a method of
selection for chromosomally normal embryos, alternative
embryo selection modalities are usually favored over this
technique. The invasiveness of many biopsy procedures is
the most important reason why specialists consider other
options first (Cohen et al., 2007; Kirkegaard et al., 2012).
Now there is a glimmer of hope that this situation could
change.
Researchers from Italy and England (Palini et al., 2013)
have for the first time sampled blastocoelic fluid from ex-
panded human blastocysts prior to vitrification and sub-
jected the contents to PCR and DNA amplification
procedures. The intervention did not involve cell biopsy.
In an earlier study the content of the human blastocoel
was analyzed by mass spectrometry in order to confirm
the presence of molecular biomarkers produced by the
embryo (Poli et al., 2012). The Palini team confirmed
the presence of cell-free genomic DNA in the blastocoelic
fluid of about 90% of the investigated embryos and several
genes were identified related to the sex of the embryo. In
a few instances chromosomes could be identified after
whole genome amplification using a commercially avail-
able array CGH kit. Although there was an indication of
the presence of fragmented DNA, genomic signals were
sufficient to establish aneuploidy. The amount of DNA
originally present in the sampled fluids was estimated to
be equivalent to one embryonic cell. Although these find-
ings are extraordinary, conclusions are still preliminary,
since the quality of the DNA will need to be further
investigated, as will the proportion of embryos in which
a diagnosis will be possible.1472-6483/$ - see front matter ª 2013, Reproductive Healthcare Ltd.
http://dx.doi.org/10.1016/j.rbmo.2013.03.001The advantages of performing PGD and PGS without
biopsy are very obvious, but the procedure proposed by
Palini and co-workers must be considered sensibly and po-
tential clinical application must be approached with cau-
tion. A number of important questions should be
addressed first by performing pre-clinical experiments using
spare human blastocysts prior to clinical application: (i)
Does the procedure sample DNA that is representative of
the embryo? Control samples were obtained from the cul-
ture droplets, but it is known that human DNA is often pres-
ent in embryo-free droplets of protein-supplemented
culture medium. A follow-up trophectoderm biopsy was
not performed, but this is an obvious second series of exper-
iments to compare cell-free DNA results with those from
biopsies. (ii) Could the DNA have been released from abnor-
mal or degenerate cells that are often excluded from the
embryo? If so, the DNA may not always be representative
of intact cells from the embryo. (iii) Is the procedure truly
non-invasive? Whereas the procedure may not extract cells,
damage may occur during the manipulation process possibly
affecting the viability of the blastocyst. (iv) Can it be proven
that the piercing of the trophectoderm and suction of fluid
does not inadvertently release cellular material from the
blastocyst, which is then aspirated and analyzed? The
authors exclude this alternative explanation theoretically,
and they may well be correct, yet the assumption needs
to be proven. (v) If DNA is dislodged into the blastocoel,
can it also be released through the pores in the zona pellu-
cida into the immediate environment? (vi) If affirmative,
can the procedure be implemented by culturing blastocysts
in minimal volumes to sample the products externally with-
out micromanipulation? Can such sampling be done before
blastocyst formation? The pursuit of this line of research
will no doubt lead to answers of these and other relevant
questions.
The work of Palini and co-workers is provocative and
fascinating for it raises the possibility of a new era in
diagnosis of genetic abnormalities in preimplantation
embryos.Published by Elsevier Ltd. All rights reserved.
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